75 HAYDEN AVENUE, LEXINGTON, MA
Leveraging Genetics to Treat Neurological Diseases 2025 Biopharma Back to School Conference September 2, 2025
Earnings Release
News
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Other Events
Financial Results, Press Release
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Confidential Treatment Order
SEC Staff Correspondence